(Q37634196)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

review article

1 reference

title

The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Alice H W Chan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Nilufar Partovi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

17 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

Annals of Pharmacotherapy

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

2044-2063

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19920162%20AND%20SRC:MED&resulttype=core&format=json

Factors predictive of a beneficial response to therapy of hepatitis C.

12 February 2020

cites work

1 reference

Hepatitis C: a review for primary care physicians

21 January 2018

1 reference

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

21 January 2018

1 reference

Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

21 January 2018

1 reference

Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.

21 January 2018

1 reference

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

21 January 2018

1 reference

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.

21 January 2018

1 reference

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

21 January 2018

1 reference

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study

21 January 2018

1 reference

Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin

21 January 2018

1 reference

Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

21 January 2018

1 reference

Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography

21 January 2018

1 reference

Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum

21 January 2018

1 reference

Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood

21 January 2018

1 reference

Determination of ribavirin in human serum and plasma by capillary electrophoresis

21 January 2018

1 reference

Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.

21 January 2018

1 reference

A sensitive and specific method for the determination of total ribavirin in human red blood cells by liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay

21 January 2018

1 reference

Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin

21 January 2018

1 reference

Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy

21 January 2018

1 reference

Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy

21 January 2018

1 reference

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models

21 January 2018

1 reference

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

21 January 2018

1 reference

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.

21 January 2018

1 reference

Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C.

21 January 2018

1 reference

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial

21 January 2018

1 reference

Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections

21 January 2018

1 reference

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors

21 January 2018

1 reference

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

21 January 2018

1 reference

Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load

21 January 2018

1 reference

Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection

21 January 2018

1 reference

Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C.

21 January 2018

1 reference

Rapid virologic response: a new milestone in the management of chronic hepatitis C.

21 January 2018

1 reference

The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon

21 January 2018

1 reference

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin

21 January 2018

1 reference

Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV.

21 January 2018

1 reference

Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients

21 January 2018

1 reference

Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study

21 January 2018

1 reference

Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency

21 January 2018

1 reference

Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.

21 January 2018

1 reference

The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant

21 January 2018

1 reference

Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.

21 January 2018

1 reference

Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation

21 January 2018

1 reference

Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection

21 January 2018

1 reference

Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.

21 January 2018

1 reference

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence

21 January 2018

1 reference

Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.

21 January 2018

1 reference

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

21 January 2018

1 reference

Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function

21 January 2018

1 reference

Pharmacokinetics of ribavirin in patients with hepatitis C virus

21 January 2018

1 reference

Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin

21 January 2018

1 reference

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference